3-(piperidylaminocarbonyl)-5-(biphenyl)-1-(4-aminosulfonylphenyl)-1H-pyrazole | 1314236-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(piperidylaminocarbonyl)-5-(biphenyl)-1-(4-aminosulfonylphenyl)-1H-pyrazole
• 英文别名: 5-(4-phenylphenyl)-N-piperidin-1-yl-1-(4-sulfamoylphenyl)pyrazole-3-carboxamide
• CAS: 1314236-17-3
• 化学式: C₂₇H₂₇N₅O₃S
• 分子量: 501.609
• InChiKey: BGPWYCOSZPAIEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-(4-aminosulfonylphenyl)-3-ethoxycarbonyl-5-(4-biphenylyl)-1H-pyrazole 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 3-(piperidylaminocarbonyl)-5-(biphenyl)-1-(4-aminosulfonylphenyl)-1H-pyrazole
  参考文献：
  名称：

  Fragment-Based Drug Design and Drug Repositioning Using Multiple Ligand Simultaneous Docking (MLSD): Identifying Celecoxib and Template Compounds as Novel Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3)

  摘要：

  We describe a novel method of drug discovery using MLSD and drug repositioning with cancer target STAT3 being used as a test case. Multiple drug scaffolds were simultaneously docked into hot spots of STAT3 by MLSD, followed by tethering to generate virtual template compounds. Similarity search of virtual hits on drug database identified celecoxib as a novel inhibitor of STAT3. Furthermore, we designed two novel lead inhibitors based on one of the lead templates and celecoxib.

  DOI：

  10.1021/jm101330h

文献信息

• Fragment-Based Drug Design and Drug Repositioning Using Multiple Ligand Simultaneous Docking (MLSD): Identifying Celecoxib and Template Compounds as Novel Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3)
  作者：Huameng Li、Aiguo Liu、Zhenjiang Zhao、Yufang Xu、Jiayuh Lin、David Jou、Chenglong Li

  DOI：10.1021/jm101330h

  日期：2011.8.11

  We describe a novel method of drug discovery using MLSD and drug repositioning with cancer target STAT3 being used as a test case. Multiple drug scaffolds were simultaneously docked into hot spots of STAT3 by MLSD, followed by tethering to generate virtual template compounds. Similarity search of virtual hits on drug database identified celecoxib as a novel inhibitor of STAT3. Furthermore, we designed two novel lead inhibitors based on one of the lead templates and celecoxib.